平衡结直肠癌化疗的疗效和毒性。
Balancing the efficacy and toxicity of chemotherapy in colorectal cancer.
机构信息
Consultant, Department of Medical Oncology, The Christie NHS Foundation Trust, Wilmslow Road, Withington, Manchester M20 4BX, UK.
出版信息
Ther Adv Med Oncol. 2011 Jan;3(1):43-52. doi: 10.1177/1758834010388342.
Abstract
As the therapeutic options for the treatment of colorectal cancer have expanded over the past 20 years, so has the complexity of decision making. The goals of treatment in the palliative, adjuvant and neoadjuvant settings vary and it is not only the efficacy of drugs that influence treatment decisions. Age, performance status, the presence of significant comorbidities and the different treatment regimens and strategies provide medical oncologists with an array of options to attempt to maximize patients' quality of life and longevity.
摘要
随着过去 20 年来治疗结直肠癌的治疗选择的不断扩展，决策的复杂性也在增加。姑息治疗、辅助治疗和新辅助治疗的目标不同，影响治疗决策的不仅是药物的疗效。年龄、体能状态、是否存在严重合并症以及不同的治疗方案和策略为肿瘤内科医生提供了一系列的选择，以尽量提高患者的生活质量和延长寿命。
相似文献
1
Balancing the efficacy and toxicity of chemotherapy in colorectal cancer.平衡结直肠癌化疗的疗效和毒性。
Ther Adv Med Oncol. 2011 Jan;3(1):43-52. doi: 10.1177/1758834010388342.
2
KRAS Testing for Anti-EGFR Therapy in Advanced Colorectal Cancer: An Evidence-Based and Economic Analysis.晚期结直肠癌抗表皮生长因子受体治疗的KRAS检测：基于证据的经济分析
Ont Health Technol Assess Ser. 2010;10(25):1-49. Epub 2010 Dec 1.
3
Management of colorectal cancer in elderly patients: focus on the cost of chemotherapy.老年患者结直肠癌的管理：关注化疗费用
Drugs Aging. 2004;21(2):113-33. doi: 10.2165/00002512-200421020-00004.
4
The use of irinotecan, oxaliplatin and raltitrexed for the treatment of advanced colorectal cancer: systematic review and economic evaluation.伊立替康、奥沙利铂和雷替曲塞用于治疗晚期结直肠癌：系统评价与经济学评估
Health Technol Assess. 2008 May;12(15):iii-ix, xi-162. doi: 10.3310/hta12150.
5
3-month versus 6-month adjuvant chemotherapy for patients with high-risk stage II and III colorectal cancer: 3-year follow-up of the SCOT non-inferiority RCT.高危 II 期和 III 期结直肠癌患者的 3 个月与 6 个月辅助化疗：SCOT 非劣效 RCT 的 3 年随访。
Health Technol Assess. 2019 Dec;23(64):1-88. doi: 10.3310/hta23640.
6
Role of oxaliplatin combined with 5-fluorouracil and folinic acid in the first- and second-line treatment of advanced colorectal cancer.奥沙利铂联合 5-氟尿嘧啶和亚叶酸在晚期结直肠癌一线和二线治疗中的作用。
Curr Oncol. 2006 Oct;13(5):173-84. doi: 10.3747/co.v13i5.99.
7
Pharmacogenomics of fluorouracil, irinotecan, and oxaliplatin in hepatic metastases of colorectal cancer: clinical implications.氟尿嘧啶、伊立替康和奥沙利铂在结直肠癌肝转移中的药物基因组学：临床意义
Am J Pharmacogenomics. 2005;5(1):21-33. doi: 10.2165/00129785-200505010-00002.
8
Current treatments and future perspectives in colorectal and gastric cancer.结直肠癌和胃癌的当前治疗方法与未来展望
Ann Oncol. 2003;14 Suppl 2:ii49-55. doi: 10.1093/annonc/mdg730.
9
Recent experience with oxaliplatin or irinotecan combined with 5-fluorouracil and leucovorin in the treatment of colorectal cancer.奥沙利铂或伊立替康联合5-氟尿嘧啶和亚叶酸钙治疗结直肠癌的近期经验。
Semin Oncol. 2003 Aug;30(4 Suppl 15):40-6. doi: 10.1016/s0093-7754(03)00404-4.
10
A systematic overview of chemotherapy effects in colorectal cancer.结直肠癌化疗效果的系统综述。
Acta Oncol. 2001;40(2-3):282-308. doi: 10.1080/02841860151116367.
引用本文的文献
1
Therapeutic efficacy of baicalein and 6-(methylsulfinyl)hexyl isothiocyanate, alone or in combination with 5-fluorouracil, in the treatment of colorectal cancer.黄芩素和6-(甲基亚磺酰基)己基异硫氰酸酯单独或与5-氟尿嘧啶联合用于治疗结直肠癌的疗效。
Naunyn Schmiedebergs Arch Pharmacol. 2025 Jun 10. doi: 10.1007/s00210-025-04274-w.
2
The Role of Frailty in the Treatment of Locally Advanced Rectal Cancer.衰弱在局部晚期直肠癌治疗中的作用
Cancers (Basel). 2024 Sep 27;16(19):3287. doi: 10.3390/cancers16193287.
3
Risk Without Reward: Differing Patterns of Chemotherapy Use Do Not Improve Outcomes in Stage II Early-Onset Colon Cancer.有风险却无回报：不同的化疗使用模式并不能改善II期早发性结肠癌的治疗结果。
JCO Oncol Pract. 2025 Mar;21(3):333-340. doi: 10.1200/OP.24.00159. Epub 2024 Jul 24.
4
Efficacy and Safety of Compound Kushen Injection for Advanced Colorectal Cancer: A Systematic Review and Meta-Analysis of Randomized Clinical Trials with Trial Sequential Analysis.复方苦参注射液治疗晚期结直肠癌有效性和安全性的系统评价和 Meta 分析：采用试验序贯分析的随机临床试验。
Integr Cancer Ther. 2024 Jan-Dec;23:15347354241258458. doi: 10.1177/15347354241258458.
5
Reactive oxygen species mediated apoptotic death of colon cancer cells: therapeutic potential of plant derived alkaloids.活性氧介导的结肠癌细胞凋亡死亡：植物衍生生物碱的治疗潜力。
Front Endocrinol (Lausanne). 2023 Jul 25;14:1201198. doi: 10.3389/fendo.2023.1201198. eCollection 2023.
6
Pan-integrin inhibitor GLPG-0187 promotes T-cell killing of mismatch repair-deficient colorectal cancer cells by suppression of SMAD/TGF-β signaling.全整合素抑制剂GLPG-0187通过抑制SMAD/TGF-β信号传导促进T细胞对错配修复缺陷型结肠癌细胞的杀伤作用。
Am J Cancer Res. 2023 Jul 15;13(7):2878-2885. eCollection 2023.
7
RPL27 contributes to colorectal cancer proliferation and stemness via PLK1 signaling.RPL27 通过 PLK1 信号通路促进结直肠癌的增殖和干性。
Int J Oncol. 2023 Aug;63(2). doi: 10.3892/ijo.2023.5541. Epub 2023 Jun 30.
8
Optimizing the safety of antibody-drug conjugates for patients with solid tumours.优化抗体药物偶联物在实体瘤患者中的安全性。
Nat Rev Clin Oncol. 2023 Aug;20(8):558-576. doi: 10.1038/s41571-023-00783-w. Epub 2023 Jun 9.
9
The dinitrobenzamide mustard prodrugs, PR-104A and SN27686, for use in a novel MNDEPT cancer prodrug therapy approach.用于新型 MNDEPT 癌症前药治疗方法的二硝基苯甲酰胺前药 PR-104A 和 SN27686。
Biosci Rep. 2023 Apr 26;43(4). doi: 10.1042/BSR20230627.
10
The Impact of Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (CRS-HIPEC) versus Conventional Surgery on Patient-Reported Outcomes: A Comparative Cohort Study between the CAIRO6 Trial and the PROCORE Study.减瘤手术与腹腔热灌注化疗（CRS-HIPEC）对比传统手术对患者报告结局的影响：CAIRO6试验与PROCORE研究的比较队列研究
Cancers (Basel). 2023 Jan 27;15(3):788. doi: 10.3390/cancers15030788.
本文引用的文献
1
Impact of age on the efficacy of newer adjuvant therapies in patients with stage II/III colon cancer: findings from the ACCENT database.年龄对 II/III 期结肠癌患者新型辅助治疗疗效的影响：ACCENT 数据库的研究结果。
J Clin Oncol. 2013 Jul 10;31(20):2600-6. doi: 10.1200/JCO.2013.49.6638. Epub 2013 Jun 3.
2
Can chemotherapy be discontinued in unresectable metastatic colorectal cancer? The GERCOR OPTIMOX2 Study.不可切除的转移性结直肠癌患者能否停用化疗？GERCOR OPTIMOX2研究。
J Clin Oncol. 2009 Dec 1;27(34):5727-33. doi: 10.1200/JCO.2009.23.4344. Epub 2009 Sep 28.
3
Clinical trial enrollment, patient characteristics, and survival differences in prospectively registered metastatic colorectal cancer patients.前瞻性登记的转移性结直肠癌患者的临床试验入组情况、患者特征及生存差异
Cancer. 2009 Oct 15;115(20):4679-87. doi: 10.1002/cncr.24527.
4
Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial.在MOSAIC试验中，奥沙利铂、氟尿嘧啶和亚叶酸作为II期或III期结肠癌辅助治疗可提高总生存率。
J Clin Oncol. 2009 Jul 1;27(19):3109-16. doi: 10.1200/JCO.2008.20.6771. Epub 2009 May 18.
5
Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer.西妥昔单抗与化疗联合作为转移性结直肠癌的初始治疗方案
N Engl J Med. 2009 Apr 2;360(14):1408-17. doi: 10.1056/NEJMoa0805019.
6
Pooled safety and efficacy analysis examining the effect of performance status on outcomes in nine first-line treatment trials using individual data from patients with metastatic colorectal cancer.汇集安全性和疗效分析，使用转移性结直肠癌患者的个体数据，检验体能状态对9项一线治疗试验结果的影响。
J Clin Oncol. 2009 Apr 20;27(12):1948-55. doi: 10.1200/JCO.2008.20.2879. Epub 2009 Mar 2.
7
Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer.转移性结直肠癌的化疗、贝伐单抗和西妥昔单抗
N Engl J Med. 2009 Feb 5;360(6):563-72. doi: 10.1056/NEJMoa0808268.
8
Toxicity associated with combination oxaliplatin plus fluoropyrimidine with or without cetuximab in the MRC COIN trial experience.MRC COIN试验中与奥沙利铂联合氟嘧啶（无论有无西妥昔单抗）相关的毒性反应经验。
Br J Cancer. 2009 Jan 27;100(2):251-8. doi: 10.1038/sj.bjc.6604877.
9
Combination of surgery and chemotherapy and the role of targeted agents in the treatment of patients with colorectal liver metastases: recommendations from an expert panel.手术与化疗联合以及靶向药物在结直肠癌肝转移患者治疗中的作用：专家小组建议
Ann Oncol. 2009 Jun;20(6):985-92. doi: 10.1093/annonc/mdn735. Epub 2009 Jan 19.
10
A randomized phase IIIB trial of chemotherapy, bevacizumab, and panitumumab compared with chemotherapy and bevacizumab alone for metastatic colorectal cancer.一项随机 IIIB 期试验：比较化疗、贝伐单抗和帕尼单抗联合治疗与单纯化疗和贝伐单抗治疗转移性结直肠癌的疗效。
J Clin Oncol. 2009 Feb 10;27(5):672-80. doi: 10.1200/JCO.2008.19.8135. Epub 2008 Dec 29.
Zotero 插件